Definium Therapeutics, Inc. (DFTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US24477V1052
Definium Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -166.31 m USD |
| EBIT | -189.27 m USD |
| Net income | -183.79 m USD |
| Diluted EPS – continuing operations | -2.06 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
More stocks
- Formosa Sumco Technology Corp (3532.TW)
- Rithm Capital Corp. (RITM)
- CSW INDUSTRIALS, INC. (CSW)
- Montage Gold Corp (MAU.V)
- Iridium Communications Inc. (IRDM)
- Suzhou Inovance Automotive Co., Ltd. (301656.SZ)
- Petronas Dagangan Bhd (5681.KL)
- Reynolds Consumer Products Inc. (REYN)
- Seatrium Limited (5E2.SI)
- Grupo Aeroportuario del Centro Norte SAB de CV (OMAB)
- Acerinox SA (ACX.MC)
- 1&1 (1U1.DE)
Not investment advice. All data without warranty, price as of 21.10.2026. Details in the risk notice.